Yes, I agree that the inhaled version is going to be the key, so I'm glad that Relief didn't wait for the U.S. FDA and started their own inhaler trials in the EU. Picking up Acer's inhaled patent was a smart move. It's much better to catch the covid patient before they become critical, and the inhaled version can do that in a cost effective way.
In the U.S., it's going to be an uphill climb to unseat FDA/Fauci's darling Remdesivir for standard of care. Remdesivir failed multiple trials and even the WHO warned against it's use, but that still has not stopped it here in the U.S. The NIH trial pairing Aviptadil with/against Remdesivir will hopefully solve the Remdesivir issue once and for all, but it's going to take awhile. I expect that RLF will get revenue from the EU before the NIH trial is finished.
News 
Market Data 
Discover 
AI
